PALATIN TECHNOLOGIES

PTN
Delayed Quote. Delayed  - 10/22 04:10:00 pm
0.4145USD -4.71%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Palatin Technologies, Inc. (Palatin), is a biopharmaceutical company. Palatin is focused on developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Palatin product candidates are targeted receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions and tissue homeostasis, and therapeutic agents modulating this system have potential to treat cardiovascular and fibrotic diseases. Palatin lead product includes Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Its other product line includes PL9643 for dry eye disease and anti-inflammatory ocular indications and Oral PL8177 for inflammatory bowel diseases.
Sales per Business
20202021
Melanocortin and Natriuretic Peptide Receptor Systems0.12100%--
USD in Million
Sales per region
20202021
United States0.12100%--
USD in Million
Managers
Name Title
Carl Spana President, Chief Executive Officer & Director
Stephen T. Wills COO, CFO, Secretary, Treasurer & Executive VP
John K. A. Prendergast Non-Executive Chairman
Michael B. Raizman Chief Medical Officer
John Dodd Senior Vice President-Preclinical Development
Robert K. deVeer Independent Director
Joseph Stanley Hull Independent Director
Alan W. Dunton Independent Director
Arlene M. Morris Independent Director
Anthony M. Manning Independent Director
Shareholders
Name Equities %
The Vanguard Group, Inc. 9,415,677 4.07%
Carl Spana 8,552,677 3.70%
Stephen T. Wills 7,640,464 3.30%
QVT Financial LP 4,296,847 1.86%
BlackRock Fund Advisors 2,954,943 1.28%
Alyeska Investment Group LP 2,385,321 1.03%
Baker Bros. Advisors LP 2,050,000 0.89%
Acadian Asset Management LLC 1,804,539 0.78%
ClariVest Asset Management LLC 1,712,000 0.74%
Geode Capital Management LLC 1,651,856 0.71%
Company contact information
Palatin Technologies, Inc.
Cedar Brook Corporate Center
4-B Cedar Brook Drive
Cranbury, NJ 08512

Phone : +1.609.495.2200
Fax : +1.609.495.2202
Web : http://www.palatin.com
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
PALATIN TECHNOLOGIES, INC.-38.67%96
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610
BEIGENE, LTD.46.63%35 360
GENMAB A/S21.44%30 583
ARGENX SE3.14%14 957
ACCELERON PHARMA INC.35.96%10 637
MIRATI THERAPEUTICS, INC.-13.36%9 823
NEUROCRINE BIOSCIENCES, INC.8.02%9 800
HUALAN BIOLOGICAL ENGINEERING INC.-29.17%8 549
ASCENDIS PHARMA A/S-13.29%8 225
LEGEND BIOTECH CORPORATION88.49%7 060
SAREPTA THERAPEUTICS, INC.-52.94%6 976
GW PHARMACEUTICALS PLC89.72%6 907
ARROWHEAD PHARMACEUTICALS, INC.-13.95%6 884
EXELIXIS, INC.6.63%6 742
REMEGEN CO., LTD.7.68%6 446
KODIAK SCIENCES INC.-21.04%5 938
Brand Portfolio
PALATIN TECHNOLOGIES
PALATIN TECHNOLOGIES
» More brands of Palatin Technologies, Inc.